Fig 1.
Baseline IgG binding to DENV2 and JEV VLP.
(A and C) Binding reactivity to (A) DENV2 or (C) JEV of children younger than 12 months versus children 12 months and older prior to vaccination (two-tailed Student’s t-test; broken lines at P/N cut-off; horizontal bars represent the mean). (B and D) Relationship between age and binding reactivity against (B) DENV2 or (D) JEV (two-tailed Spearman rank correlation test). (E) Relationship between DENV2 and JEV binding reactivities (two-tailed Spearman rank correlation test).
Fig 2.
Antibody response to IMOJEV vaccination.
(A) Comparison of log10 JEV RVPNT50 titers pre- and post-vaccination (one-tailed paired Student’s t-test; titers less than 10 were assigned a value of 5). (B) Pairwise comparison of JEV VLP IgG binding reactivity pre- and post-vaccination (one-tailed paired Student’s t-test; in red is subject B27, who did not respond to vaccination based on the RVP neutralization assay). (C and D) Comparison of post-vaccination log10 JEV RVPNT50 titers (C) between age groups and (D) by DENV2 reactivity (two-tailed unpaired Student’s t-test).
Fig 3.
DENV2 binding reactivity and functional antibody responses.
(A) Pairwise comparison of DENV2 VLP IgG binding reactivity pre- and post-vaccination (one-tailed paired Student’s t-test). (B) Relationship between the fold change in DENV2 and JEV VLP IgG ELISA P/N values after vaccination (one-tailed Spearman rank correlation test). (C and D) Pairwise comparison of DENV2 neutralizing titers or fold enhancement post-JEV immunization (two-tailed paired Student’s t-test; broken lines at cut-off for neutralization or enhancement and shown in red circles is subject B27 who did not respond to JEV vaccination; in Fig 3C, the line at y = 0.7 represents 13 subjects that did not have neutralizing activity pre- and post-vaccination).
Table 1.
Serum dilution at peak fold enhancement of DENV2.